E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

  • Law Blogs

Become a Fan

« News from Abroad: COFEMER and AMELAF Comment on Biotech Regulations in Mexico | Main | News from Abroad: Mexican Patent Office Excludes Formulation Patents from Linkage Gazette »

August 17, 2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83451ca1469e20133f31e1057970b

Listed below are links to weblogs that reference American Bar Association Files Amicus Brief in Therasense Case:

Comments

The "vagueness" argument is a ploy.

Applying only a "but-for, fraud level" test misses an extensive amount of "other" bad conduct which ia actually (and conveniently?) left out of the references to case law.

The comments to this entry are closed.

September 2014

Sun Mon Tue Wed Thu Fri Sat
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30